Company intelligence / Profile preview

NeuroBiogen

South Korea

Ownership: Private
Development stage: Other

Overview

NeuroBiogen's lead candidate KDS2010, a reversible selective MAO-B inhibitor, has shown promising cognitive improvement in preclinical and Phase 1 studies. It is currently in Phase 2 clinical trials in obesity and Alzheimer's disease, with evidence suggesting reduction in astrocytic GABA signaling and neuroinflammation, translating to improved learning and memory in trial subjects.[2][3][6]

Therapeutic areas: OncologyNeurologyEndocrinologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Scilex Bio (part of Scilex Holding Company)

Beyond the preview

Go deeper on NeuroBiogen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NeuroBiogen.

Explore the full profile